BioNTech completes acquisition of Neon Therapeutics

Published: 7-May-2020
Finance Pharmaceutical

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases

BioNTech has announced the closing of the Neon Therapeutics acquisition through an all-stock transaction.

The merger agreement was first announced on 16 January 2020.

The new subsidiary, based in Cambridge (MA, US), will operate under the name of BioNTech US Inc. and serve as BioNTech’s US headquarters.

As of May 7 2020, Neon’s common stock will no longer be available for trading.

  • Companies:
  • BioNTech AG
See more

You may also like

Finance

BioNTech and Autolus announce strategic collaboration

Read more
The strategic collaboration will advance both companies' autologous CAR-T programmes towards commercialisation, pending regulatory authorisations

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

BioNTech and Autolus announce strategic collaboration

The strategic collaboration will advance both companies' autologous CAR-T programmes towards commercialisation, pending regulatory authorisations
Ingredients

Pfizer and BioNTech announce early positive vaccine update

Collaboration has announced results from German Phase 1/2 COVID-19 vaccine study, including first T-Cell response data
Research & Development

BioNTech and Siemens cooperate on production of personalised cancer vaccines

Siemens will develop and construct an automated and paperless manufacturing site
Research & Development

EU-funded consortium to advance personalised cancer vaccines into trials

First centres to enrol glioblastoma patients are opened in Heidelberg and Tuebingen in Germany
Media

BioNTech acquires Eufets

<p>German biotech company BioNTech has acquired Eufets from Fresenius Biotech. Eufets is a GMP and GLP services specialist and under its new owner will retain all facilities, staff and contracts of the former company.</p>
Finance

Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China

New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
Finance

Newcells Biotech raises additional funding from investors

Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
Subscribe now